CXCL14 AS PREDICTIVE BIOMARKER FOR ACUTE LIVER FAILURE AND DEATH

Abstract

A method of determining a likelihood of liver transplant can be performed on a subject that has consumed acetaminophen at an initial time point and has been diagnosed with hepatotoxicity. The amount of CXCL14 in the blood samples to the series of time points can be measured to determine a trend in the amount of the CXCL14 in the blood samples over a time period beginning at the initial time point and continuing through the series of time points. The trend can be: (a) the amount of CXCL14 increases over the time period - the treatment is determined to be a liver transplant; (b) the amount of CXCL14 increases and then becomes substantially constant the treatment is determined to be a liver transplant; or (c) the amount of CXCL14 has a maximum (> 3000) and then decreases - the treatment is determined to exclude a liver transplant.

Description

Claims

1. A method of determining a likelihood of liver transplant in a subject, comprising: providing a subject having consumed acetaminophen and having been diagnosed with hepatotoxicity;obtaining a plurality of blood samples from the subject at a series of time points over a plurality of days;measuring an amount of CXCL14 in the blood sample at the series of time points;comparing the amount of CXCL14 in the blood samples to the series of time points to determine a trend in the amount of the CXCL14 in the blood samples over a time period beginning at an time point and continuing through the series of time points;identifying a trend of: (a) the amount of CXCL14 increases over the time period;(b) the amount of CXCL14 increases and then becomes substantially constant; or(c) the amount of CXCL14 has a maximum and then decreases;selecting the trend in the amount of CXCL14 in the blood over the time period that matches the trend of (a), (b), or (c);determining a treatment of the subject based on the trend in the amount of CXCL14 in the blood samples over the time period, wherein the treatment is selected from: when the amount of CXCL14 increases over the time period, the treatment is determined to be a liver transplant;when the amount of CXCL14 increases and then becomes substantially constant, the treatment is determined to be a liver transplant; orwhen the amount of CXCL14 has a maximum and then decreases, the treatment is determined to exclude a liver transplant;preparing a report that identifies the treatment for the subject; andproviding the report to the subject or medical professional or medical computing system.

2. The method of claim 1, wherein the time period is at least 2 days.

3. The method of claim 1, wherein the time period is at least 3 days.

4. The method of claim 1, wherein in trend (c) the amount of CXCL14 starts at a maximum and then decreases.

5. The method of claim 1, wherein in trend (c) the amount of CXCL14 increases to a maximum and then decreases.

6. The method of claim 1, wherein when the amount of CXCL14 is at least 3,000 pg/mL in plasma from the blood, the treatment is the liver transplant.

7. The method of claim 1, wherein when the amount of CXCL14 is at least 5,000 pg/mL in plasma, the treatment is the liver transplant.

8. The method of claim 1, further comprising measuring at least one of ALT, bilirubin, or prothrombin.

9. The method of claim 8, wherein data from the measuring of at least one of ALT, bilirubin, or prothrombin supports the treatment.

10. The method of claim 9, wherein measurement of prothrombin at a plurality of time points supports the treatment.

11. A method of treating a subject having hepatotoxicity, comprising: providing a subject having consumed acetaminophen and having been diagnosed with hepatotoxicity;obtaining a plurality of blood samples from the subject at a series of time points over a plurality of days;measuring an amount of CXCL14 in the blood sample at the series of time points;comparing the amount of CXCL14 in the blood samples to the series of time points to determine a trend in the amount of the CXCL14 in the blood samples over a time period beginning at the initial time point and continuing through the series of time points;identifying a trend of: (a) the amount of CXCL14 increases over the time period;(b) the amount of CXCL14 increases and then becomes substantially constant; or(c) the amount of CXCL14 has a maximum and then decreases; selecting the trend in the amount of CXCL14 in the blood over the time period that matches the trend of (a), (b), or (c);determining a treatment of the subject based on the trend in the amount of CXCL14 in the blood samples over the time period, wherein the treatment is selected from:when the amount of CXCL14 increases over the time period, the treatment is determined to be a liver transplant;when the amount of CXCL14 increases and then becomes substantially constant, the treatment is determined to be a liver transplant; orwhen the amount of CXCL14 increases to a maximum and then decreases, the treatment is determined to exclude a liver transplant; and coordinating performance of the treatment on the subject.

12. The method of claim 11, further comprising performing the treatment on the subject.

13. The method of claim 11, wherein the treatment includes the liver transplant.

14. The method of claim 11, wherein the treatment excludes the liver transplant.

15. The method of claim 11, wherein the time period is at least 2 days.

16. The method of claim 11, wherein the time period is at least 3 days.

17. The method of claim 11, wherein in trend (c) the amount of CXCL14 starts at a maximum and then decreases.

18. The method of claim 11, wherein in trend (c) the amount of CXCL14 increases to a maximum and then decreases.

19. The method of claim 11, wherein when the amount of CXCL14 is at least 3,000 pg/mL in plasma from the blood, the treatment is the liver transplant.

20. The method of claim 1, wherein when the amount of CXCL14 is at least 5,000 pg/mL in plasma, the treatment is the liver transplant.